The growing role of clinical and genomic databases in the development of antifungal strategies

Research output: Contribution to journalArticle

Abstract

Decisions about the prophylactic and empiric use of antifungal agents in immunosuppressed recipients of solid-organ transplants and hematopoietic stem cell transplantation (HSCT) call for up-to-date knowledge regarding which infections are most likely to develop in the populations at risk, but rapidly changing immunosuppressive regimens and the costs of large-scale clinical trials require new ways of gathering these data. Leveraging new clinical data from electronic databases to better understand the changing epidemiology of invasive fungal infection and the patterns of risk factors for adverse effects of antifungal treatment offers a major challenge and opportunity. Evidence-based integration of results generated from traditional prospective clinical trials, clinical and genomic databases, and laboratory-based investigations will enable us to maximize the potential benefits of antifungal agents and reduce their risks.

Original languageEnglish (US)
Pages (from-to)190-192
Number of pages3
JournalCurrent Fungal Infection Reports
Volume5
Issue number4
DOIs
Publication statusPublished - 2011

    Fingerprint

Keywords

  • Adverse effects
  • Antifungal agents
  • Clinical databases
  • Databases
  • Fungal infection
  • Genomic databases
  • Genomics
  • Hematopoietic stem cell transplantation
  • HSCT
  • Immunosuppression
  • Prophylaxis
  • Risk factors
  • Solid-organ transplants
  • Treatment

ASJC Scopus subject areas

  • Infectious Diseases

Cite this